drugset / Trial / NCT06553872
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2
Recruiting
60 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bankhead-Coley Florida Biomedical Research Program · collabEli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
Timeline
- Start
- 2024-08-23
- Primary completion
- 2029-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirtobrutinib | Other / unclassified | — | — |
| Background | Brexucabtagene Autoleucel | Cell therapy | — | — |